A PHASE II STUDY OF Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 02 May 2018
Price : $35 *
At a glance
- Drugs Deferasirox (Primary) ; Azacitidine
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 19 May 2017 Planned End Date changed from 1 Oct 2016 to 1 Jun 2019.
- 19 May 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2018.